Related Experiment Video
Updated: May 19, 2026
12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
Coagulation Factor IX for Hemophilia B Therapy
N A Orlova1, S V Kovnir, I I Vorobiev
1Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences.
Acta Naturae
|August 9, 2012
Summary
Hemophilia B is a bleeding disorder caused by low functional Factor IX (FIX) levels. This review covers FIX manufacturing, improved therapies, and gene therapy advances for hemophilia B treatment.
Area of Science:
- Biochemistry
- Hematology
- Biotechnology
Background:
- Factor IX (FIX) is a crucial enzyme in the blood coagulation cascade.
- Inherited deficiencies in functional FIX lead to hemophilia B, a serious bleeding disorder.
- Current treatment relies on continuous protein replacement therapy.
Purpose of the Study:
- To review the current manufacturing processes for Factor IX.
- To discuss improved recombinant FIX variants for therapeutic use.
- To explore advancements in transgenic production and gene therapy for hemophilia B.
Main Methods:
- Literature review of FIX manufacturing.
- Analysis of recombinant FIX protein engineering.
- Survey of transgenic approaches for FIX production.
- Overview of gene therapy strategies for hemophilia B.
Main Results:
- Current manufacturing methods for FIX are established.
- Engineered FIX variants show potential for improved therapeutic profiles.
- Transgenic organisms offer alternative production systems for FIX.
- Gene therapy presents promising avenues for long-term hemophilia B treatment.
Conclusions:
- Significant progress has been made in FIX production and therapeutic development.
- Improved FIX variants and novel production methods are enhancing treatment options.
- Gene therapy holds transformative potential for managing hemophilia B.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...